Prescription Dermatology
Ruxolitinib Cream (OPZELURA)
Topical JAK1/2 inhibitor for AD and vitiligo
Duration
topical1 days2 sessions (ラベル準拠)
Downtime
なし
Sessions
反応評価しながら継続
About This Treatment
Ruxolitinib 1.5% cream is a topical JAK inhibitor used for mild-to-moderate atopic dermatitis and nonsegmental vitiligo, with rapid itch relief reported.
Mechanism of Action
It suppresses local JAK1/2 signaling in skin, reducing inflammatory cytokine pathways and itch signaling.
Indications
General indication (see detailed description)
Expected Results
Analyses from TRuE-AD studies showed rapid improvements in AD signs and itch, with supportive long-term safety extension data.
Clinical Evidence
Papp K, et al. (2023)
Rapid improvement across body regions with ruxolitinib cream (TRuE-AD pooled). Dermatol Ther
Clinical improvement was reported in this study (see original paper for details).
Eichenfield LF, et al. (2023)
Long-term safety and disease control with ruxolitinib cream. J Am Acad Dermatol
Clinical improvement was reported in this study (see original paper for details).
U.S. FDA (2022)
OPZELURA prescribing information. FDA label
Clinical improvement was reported in this study (see original paper for details).
Risks & Side Effects
Application-site reactions, acneiform eruptions, and URTI may occur. Class warnings for JAK inhibitors (serious infection, thrombosis, malignancy) require careful duration/area control.
Interested in this treatment?
Start with an AI skin analysis to check your current skin condition